Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2017

Romatoid Artritte Baricitinib'e Karşı Plasebo veya Adalimumab’ın Değerlendirildiği Bir Faz 3 Çalışmasından Hasta Bildirimli Sonuçlar: RA-BEAM Çalışmasından İkincil Analizler

Ann Rheum Dis 2017;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259

Gaich C,

Dudek A,

Covarrubias Cobos JA,

Arora V,

This paper describes the patient-reported outcome (PRO) data collected in RA-BEAM, a Phase 3 study of baricitinib compared with both placebo and adalimumab in patients with RA and an inadequate response to MTX.PRO measures evaluated include health-related quality of life (HRQOL), physical function, disability, fatigue, sleep, mental health status, work productivity and work activity impairment. The RA-BEAM study demonstrated that patients treated with baricitinib experienced a greater improveme...

Keywords:

February 2017

Konvansiyonel Sentetik DMARD'lara Yetersiz Yanıtlı veya İntoleransı Olan RA Hastalarında Baricitinib Tedavisi: RA-BUILD Çalışmasının Sonuçları

Ann Rheum Dis 2017;76:88–95.

Liu J,

Witt S,

Gaich C,

Baricitinib improved symptoms of RA in the RA-BUILD trial, a Phase 3 study of baricitinib in patients with moderately to severely active RA, refractory to or intolerant to csDMARDs. As well as providing a short-term (24 weeks) benefit, there appeared to be joint damage benefit, considered a marker of long-term disability.RA-BUILD was a 24-week randomised, double-blind, placebo-controlled parallel-group study. Patients were randomised 1:1:1 to receive once-daily doses of placebo (n=228) or barici...